A Phase 3 interventional study of Tirzepatide in Type 1 Diabetes (T1D), sponsored by University of Bern. Recruiting at 3 sites in Switzerland. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-26.
Sponsored by University of Bern · Phase 3, Interventional, and Treatment
How we know · 3 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies in Diabetes Mellitus, Type 1 with a site in Switzerland — 9 open to participants now, 10 under way, 4 of them phase 3. Diabetes Mellitus, Type 1 · Switzerland.
Among the 70 studies in Diabetes Mellitus, Type 1 with a site in Switzerland, this one is the 22nd largest by planned enrollment of the 52 interventional ones that give a count, is one of 4 that started in 2025, is one of 13 in phase 3, and was the 64th registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →9 of the 70 studies in Diabetes Mellitus, Type 1 with a site in Switzerland are open now. Recruiting first, the newest first:
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Switzerland, Canada
Ages 18+
DCB Research AG · Sites in Switzerland
Ages 18–40 · Women only
Sanofi · Sites in Switzerland, United States, Argentina and 17 more countries
Ages 1–25
Pediatric Clinical Research Platform · Sites in Switzerland
Ages 0–25 · Healthy volunteers
University Hospital, Geneva · Sites in Switzerland
Ages 2–18 · Healthy volunteers
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 13 · Phase 3 16
First in 1997; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 42 is close to the median of 40 across 2,824 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 29 across the 52 interventional studies, 73 across the 18 observational. Of the 55 that completed or were terminated, 6 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 70 have an industry lead sponsor. The 10 most frequent:
University of Bern is the lead sponsor of 209 studies on the registry; 46 are open to participants now.
University of Bern has 2 studies filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
3 of the studies in Diabetes Mellitus, Type 1 with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05594706University Hospital, GenevaAnhydroglucitol in Children With Type 1 Diabetes | 2026-12-31 |
| NCT05791201Vertex Pharmaceuticals IncorporatedA Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes | 2027-03-12 |
| NCT06282055DCB Research AGTrajectories in Insulin Sensitivity Across MEnstrual cycleS in Women With Type 1 Diabetes | 2027-09-15 |
Add all 3 to your calendar (.ics) → With an account.
Among the 70 studies in Diabetes Mellitus, Type 1 with a site in Switzerland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Blood glucose management in type 1 diabetes (T1D) remains a challenge, with only \~30% of adults within the recommended consensus guidelines. Novel drugs like glucagon-like peptide-1 receptor agonists (GLP-1RAs) and glucose-dependent insulinotropic polypeptide (GIP)/GLP-1RAs have emerged as promising add-ons to insulin in T1D.
This application has been designed to test in a prospective study whether adding a new medicine called tirzepatide (GIP/GLP-1RA) to the usual insulin therapy would make a difference for people with T1D in terms of better glucose control.
Glycemic control in type 1 diabetes (T1D) remains a challenge, with \~30% of adults achieving an A1c target of 7%. The glucagon-like peptide-1 receptor agonists (GLP-1RAs) and glucose-dependent insulinotropic polypeptide (GIP)/GLP-1RAs have emerged as a promising therapy in T1D. Retrospective studies have shown patients with T1D can significantly improve glycemic control with a reduction in insulin dose and body weight when long-acting GLP-1RAs or GIP/GLP-1RAs are added to insulin therapy. However, randomized controlled trials (RCT) are still lacking.
This is a prospective, randomized, open-label design. The investigators will enroll 42 participants over 18 years of age with confirmed T1D diagnosis ≥6 months, currently on automatic insulin delivery (AID) therapy for at least three months, with A1C ≥6.5% and ≤10%and BMI ≥23 kg/m2. Participants will be randomized in a 1:1 ratio to either tirzepatide 5.0 mg or continue with the Standard of Care (SoC) for 12 weeks (after a titration phase with the lowest dose of 2.5 mg). The primary endpoint is continuous glucose monitoring (CGM) percent time spent between 3.9 and 10.0 mmol/L (TIR) from baseline to follow-up after 12 weeks of treatment. Secondary endpoints include the change in 24/7 CGM percent time \>10.0 mmol/L, 24/7 CGM percent time \>13.9 mmol/L, 24/7 CGM percent time \<3.9 mmol/L, 24/7 CGM percent time \<3.0 mmol/L and the change in body mass index (BMI).
This is the first prospective study to investigate the efficacy and safety of tirzepatide (GIP/GLP1-RAs) as an adjuvant therapy to AID. This study may contribute unique data to significantly improving glucose outcomes, reducing the T1D burden, improving the quality of life, and re-directing attention to further treatment in T1D beyond insulin therapies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this arm will use their standard of care (SoC)
Participants in this arm will use their standard of care (SoC) plus tirzepatide (titrated to reach a minimum accepted dose.
Drug: Tirzepatide
Tirzepatide is a clear, colorless to slightly yellow solution available in cartons containing four pre-filled single-dose pens or one single-dose vial: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL in a single-dose pen or vial. In this study, the investigators will start with the recommended starting dosage of tirzepatide: 2.5 mg injected subcutaneously once weekly (for four weeks). After four weeks, the dosage will be increased to 5 mg once weekly injected subcutaneously for 12 weeks.
Also known as: GIP/GLP-1RA
Change TIR
Mean difference in 24/7 CGM percentage time spent between 3.9 and 10 mmol/L (TIR) between groups.
Time frame: At week 16 of treatment.
Glycated Hemoglobin
Mean difference between groups Glycated Hemoglobin.
Time frame: At week 16 of treatment.
CGM-measured TIR between 0700 and 2300 (TIR7-23)
Mean difference between groups in CGM-measured TIR between 0700 and 2300 (TIR7-23).
Time frame: At week 16 of treatment.
CGM-measured time in the tight range (TTR, 3.9-7.8 mmol/L)
Mean difference between groups in CGM-measured time in the tight range (TTR, 3.9-7.8 mmol/L).
Time frame: At week 16 of treatment.
24/7 CGM-measured percent time >10.0 mmol/L
Mean difference between groups in 24/7 CGM-measured percent time \>10.0 mmol/L
Time frame: At week 16 of treatment.
24/7 CGM-measured percent time >13.9 mmol/L
Mean difference between groups in 24/7 CGM-measured percent time \>13.9 mmol/L
Time frame: At week 16 of treatment.
24/7 CGM-measured percent time <3.9 mmol/L
Mean difference between groups in 24/7 CGM-measured percent time \<3.9 mmol/L
Time frame: at week 16 of treatment
24/7 CGM-measured percent time <3.0 mmol/L
Mean difference between groups in 24/7 CGM-measured percent time \<3.0 mmol/L
Time frame: At week 16 of treatment.
24/7 Total Daily Insulin (TDI)
Mean difference between in 24/7 Total Daily Insulin (TDI)
Time frame: At week 16 of treatment.
CGM-measured TIR between 0700 and 2300 (TIR7-23)
Mean difference between groups in CGM-measured TIR between 0700 and 2300 (TIR7-23).
Time frame: At week 8, 12 and 16 of treatment.
24/7 CGM-measured percent time >10.0 mmol/L
Mean difference between groups in 24/7 CGM-measured percent time \>10.0 mmol/L
Time frame: At week 8, 12 and 16 of treatment.
24/7 CGM-measured percent time >13.9 mmol/L
Mean difference between groups in 24/7 CGM-measured percent time \>13.9 mmol/L
Time frame: At week 8, 12 and 16 of treatment.
24/7 CGM-measured percent time <3.9 mmol/L
Mean difference between groups in 24/7 CGM-measured percent time \<3.9 mmol/L
Time frame: At week 8, 12 and 16 of treatment.
24/7 CGM-measured percent time <3.0 mmol/L
Mean difference between groups in 24/7 CGM-measured percent time \<3.0 mmol/L
Time frame: At week 8, 12 and 16 of treatment.
CGM-measured glucose variability (CV)
CGM-measured glucose variability measured with the coefficient of variation (CV)
Time frame: At week 8, 12 and 16 of treatment.
24/7 Total Daily Insulin (TDI)
Mean difference between in 24/7 Total Daily Insulin (TDI)
Time frame: At week 8, 12 and 16 of treatment.
24/7 Total Daily Bolus (TDBo)
Mean difference between in 24/7 Total Daily Bolus (TDBo)
Time frame: At week 8, 12 and 16 of treatment.
Body Weight (BW)
Mean difference between groups in BW
Time frame: At week 16 of treatment.
Waist Circumference (WC)
Mean difference between groups in WC
Time frame: At week 16 of treatment
Hip circumference
Mean difference between the groups in hip circumference
Time frame: At week 16 of treatment.
Waist-to-hip ratio
Mean difference between groups in Waist-to-hip ratio
Time frame: At week 16 of treatment.
% Fat mass
Mean difference between groups in % fat mass
Time frame: At week 16 of treatment.
Fat mass index
Mean difference between groups in Fat mass index
Time frame: At week 16 of treatment.
Visceral adipose tissue
Mean difference between groups in visceral adipose tissue
Time frame: At week 16 of treatment.
Lean Mass Index
Mean difference between groups in Lean Mass Index
Time frame: At week 16 of treatment.
Appendicular Lean Mass Index
Mean difference between groups in Appendicular Lean Mass Index
Time frame: At week 16 of treatment.
Cholesterol LDL
Mean difference between groups in Cholesterol LDL
Time frame: At week 16 of treatment.
Cholesterol HDL
Mean difference between groups in Cholesterol HDL
Time frame: At week 16 of treatment.
Cholesterol non-HDL
Mean difference between groups in cholesterol non-HDL
Time frame: At week 16 of treatment.
Triglycerides
Mean difference between groups in Triglycerides
Time frame: At week 16 of treatment.
TG-glucose index
Mean difference between groups in TG-glucose index
Time frame: At week 16 of treatment.
Systolic blood pressure
Mean difference between groups in systolic blood pressure
Time frame: At week 16 of treatment.
Diastolic blood pressure
Mean difference between groups in diastolic blood pressure
Time frame: At week 16 of treatment.
Albumin to Creatinine Ratio
Mean difference between groups in Albumin to Creatinine Ratio
Time frame: At week 16 of treatment.
Hepatic Steatosis Index (HSI)
Mean difference between groups in HSI
Time frame: At week 16 of treatment.
Fibrosis Score (FIB-4)
Mean difference between groups in FIB-4
Time frame: At week 16 of treatment.
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2025 (actual). Primary completion is estimated for Jun 2026, 16 months after the start.
Of 108 phase 3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 27. This study's planned 16 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tirzepatide